US pharmaceutical giant Eli Lilly is set to significantly expand its presence in India through a series of strategic initiatives, reinforcing the country as a key hub in its global operations. The company announced plans to invest over $1 billion in the coming years to bolster contract manufacturing partnerships, enhance global supply chains, and increase access to innovative medicines worldwide.
Strategic Investments and Contract Manufacturing
Eli Lilly’s investment will focus on contract manufacturing tie-ups, enabling the company to expand production capacity for both current and future medicines. While the company did not disclose specific partners, locations, or products, officials emphasized that these agreements will support treatments for diabetes, obesity, Alzheimer’s, cancer, and autoimmune conditions, as well as prepare for next-generation therapies.
Patrik Jonsson, EVP and President of Lilly International, said, “This investment reaffirms our confidence in India as a hub for capability building within our global network.” Since 2020, Lilly has committed over $55 billion globally for facility expansions and acquisitions, and India is now poised to play a central role in this growth trajectory.
Expanding Weight Loss and Diabetes Portfolio
A key focus for Eli Lilly in India is its weight loss and diabetes portfolio. The company is preparing to launch an oral version of its experimental weight-loss drug, orforglipron, following the global success of the injectable Mounjaro (tirzepatide). India, with an anti-obesity drug market valued at around ₹752 crore, is considered a crucial market for the new drug. Regulatory submissions for chronic weight management and obesity are expected by the end of 2025, with approvals likely across multiple countries in the second half of 2026.
New Manufacturing and Quality Hub in Hyderabad
As part of its expansion, Eli Lilly plans to establish a new manufacturing and quality hub in Hyderabad. This center will offer advanced technical capabilities, provide oversight for contract manufacturing partners, and generate new employment opportunities for engineers, chemists, analytical scientists, and quality control professionals.
The move highlights India’s growing importance in global pharma supply chains and Lilly’s commitment to scaling operations to meet increasing international demand. By leveraging India’s skilled workforce and cost-effective manufacturing capabilities, the company aims to accelerate access to critical medicines while strengthening its global production network.
